• Something wrong with this record ?

Novel Iodinated Hydrazide-hydrazones and their Analogues as Acetyl- and Butyrylcholinesterase Inhibitors

M. Krátký, Š. Štěpánková, M. Brablíková, K. Svrčková, M. Švarcová, J. Vinšová

. 2020 ; 20 (23) : 2106-2117. [pub] -

Language English Country United Arab Emirates

Document type Journal Article

Grant support
20-19638Y Czech Science Foundation - International
CZ.02.1.01/0.0/0.0/16_019/0000841 EFSA-CDN (Charles University) - International

BACKGROUND: Hydrazide-hydrazones have been known as scaffold with various biological activities including inhibition of acetyl- (AChE) and butyrylcholinesterase (BuChE). Cholinesterase inhibitors are mainstays of dementias' treatment. OBJECTIVE: Twenty-five iodinated hydrazide-hydrazones and their analogues were designed as potential central AChE and BuChE inhibitors. METHODS: Hydrazide-hydrazones were synthesized from 4-substituted benzohydrazides and 2-/4- hydroxy-3,5-diiodobenzaldehydes. The compounds were investigated in vitro for their potency to inhibit AChE from electric eel and BuChE from equine serum using Ellman's method. We calculated also physicochemical and structural parameters for CNS delivery. RESULTS: The derivatives exhibited a moderate dual inhibition with IC50 values ranging from 15.1-140.5 and 35.5 to 170.5 μmol.L-1 for AChE and BuChE, respectively. Generally, the compounds produced a balanced or more potent inhibition of AChE. N'-[(E)-(4-Hydroxy-3,5-diiodophenyl)methylidene]-4- nitrobenzohydrazide 2k and 4-fluoro-N'-(2-hydroxy-3,5-diiodobenzyl)benzohydrazide 3a were the most potent inhibitors of AChE and BuChE, respectively. Structure-activity relationships were established, and molecular docking studies confirmed interaction with enzymes. CONCLUSION: Many novel hydrazide-hydrazones showed lower IC50 values than rivastigmine against AChE and some of them were comparable for BuChE to this drug used for the treatment of dementia. They interact with cholinesterases via non-covalent binding into the active site. Based on the BOILEDEgg approach, the majority of the derivatives met the criteria for blood-brain-barrier permeability.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020807
003      
CZ-PrNML
005      
20210830102441.0
007      
ta
008      
210728s2020 ts f 000 0|eng||
009      
AR
024    7_
$a 10.2174/1568026620666200819155503 $2 doi
035    __
$a (PubMed)32814531
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ts
100    1_
$a Krátký, Martin $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
245    10
$a Novel Iodinated Hydrazide-hydrazones and their Analogues as Acetyl- and Butyrylcholinesterase Inhibitors / $c M. Krátký, Š. Štěpánková, M. Brablíková, K. Svrčková, M. Švarcová, J. Vinšová
520    9_
$a BACKGROUND: Hydrazide-hydrazones have been known as scaffold with various biological activities including inhibition of acetyl- (AChE) and butyrylcholinesterase (BuChE). Cholinesterase inhibitors are mainstays of dementias' treatment. OBJECTIVE: Twenty-five iodinated hydrazide-hydrazones and their analogues were designed as potential central AChE and BuChE inhibitors. METHODS: Hydrazide-hydrazones were synthesized from 4-substituted benzohydrazides and 2-/4- hydroxy-3,5-diiodobenzaldehydes. The compounds were investigated in vitro for their potency to inhibit AChE from electric eel and BuChE from equine serum using Ellman's method. We calculated also physicochemical and structural parameters for CNS delivery. RESULTS: The derivatives exhibited a moderate dual inhibition with IC50 values ranging from 15.1-140.5 and 35.5 to 170.5 μmol.L-1 for AChE and BuChE, respectively. Generally, the compounds produced a balanced or more potent inhibition of AChE. N'-[(E)-(4-Hydroxy-3,5-diiodophenyl)methylidene]-4- nitrobenzohydrazide 2k and 4-fluoro-N'-(2-hydroxy-3,5-diiodobenzyl)benzohydrazide 3a were the most potent inhibitors of AChE and BuChE, respectively. Structure-activity relationships were established, and molecular docking studies confirmed interaction with enzymes. CONCLUSION: Many novel hydrazide-hydrazones showed lower IC50 values than rivastigmine against AChE and some of them were comparable for BuChE to this drug used for the treatment of dementia. They interact with cholinesterases via non-covalent binding into the active site. Based on the BOILEDEgg approach, the majority of the derivatives met the criteria for blood-brain-barrier permeability.
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a zvířata $7 D000818
650    _2
$a butyrylcholinesterasa $x metabolismus $7 D002091
650    _2
$a cholinesterasové inhibitory $x chemická syntéza $x chemie $x farmakologie $7 D002800
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a Electrophorus $7 D004593
650    _2
$a koně $7 D006736
650    _2
$a hydraziny $x chemická syntéza $x chemie $x farmakologie $7 D006834
650    _2
$a hydrazony $x chemická syntéza $x chemie $x farmakologie $7 D006835
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a molekulární struktura $7 D015394
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
700    1_
$a Štěpánková, Šárka $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic
700    1_
$a Brablíková, Michaela $u Unipetrol Centre of Research and Education, 436 70 Litvínov-Záluží 1, Czech Republic
700    1_
$a Svrčková, Katarína $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic
700    1_
$a Švarcová, Markéta $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic $u Department of Chemistry, Faculty of Science, J. E. Purkinje University, Eeske mladeze 8, 400 96 Usti nad Labem, Czech Republic
700    1_
$a Vinšová, Jarmila $u Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
773    0_
$w MED00007896 $t Current topics in medicinal chemistry $x 1873-4294 $g Roč. 20, č. 23 (2020), s. 2106-2117
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32814531 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102442 $b ABA008
999    __
$a ok $b bmc $g 1691398 $s 1141253
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 20 $c 23 $d 2106-2117 $e - $i 1873-4294 $m Current topics in medicinal chemistry $n Curr Top Med Chem $x MED00007896
GRA    __
$a 20-19638Y $p Czech Science Foundation $2 International
GRA    __
$a CZ.02.1.01/0.0/0.0/16_019/0000841 $p EFSA-CDN (Charles University) $2 International
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...